Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Wearable Sensor Detects Early Signs of Endocrine Diseases More Accurately Than Existing Tests

By HospiMedica International staff writers
Posted on 22 Jun 2023

Life-essential stress hormones like cortisol, when disrupted by disease or lifestyle factors, can contribute to conditions such as depression, heart disease, obesity, diabetes, and even severe illness. More...

Understanding the results of a hormone test is tough or nearly impossible if just a single time point is taken, as this does not consider hormonal rhythms, resulting in delayed diagnoses and missed treatment opportunities. Until recently, understanding hormonal rhythms required multiple blood samples during hospital or research unit stays, a process that was cumbersome, intrusive, and stressful.

Now, a groundbreaking wearable device developed by endocrine researchers enables early detection of diseases related to imbalanced stress hormone levels. For the first time, fluctuations in stress hormones can be monitored during typical daily activities, including day and night periods, with the wearable device. The new collaborative research that included researchers at the University of Bristol (Bristol, UK) could radically transform the diagnosis and treatment of stress hormone system diseases. Worn around the waist, the wearable device named U-RHYTHM painlessly and automatically takes samples from under the skin every 20 minutes, eliminating the need for blood collection. Importantly, it allows sampling during sleep, work, and other daily activities for up to 72 hours in one session.

In a study to examine the U-RHYTHM's potential, the researchers analyzed samples from 214 healthy volunteers over a 24-hour span. By using multiple data points throughout this period, the researchers generated adrenal hormone profiles reflecting the real-life conditions of healthy individuals. Mathematicians then used this information to develop a new category of "dynamic markers" in order to better comprehend how a healthy hormonal profile should appear, taking into account factors like sex, age, and body mass index. These results provide a snapshot of healthy hormonal rhythms in real-world scenarios, potentially serving as a baseline for improved, earlier diagnosis of endocrine conditions.

"Our results represent a paradigm shift in the understanding of how the stress hormone system works in healthy people," said Dr. Thomas Upton, Clinical Research Fellow in Automated Sampling at the University of Bristol and lead endocrinologist in the study. "The information we have gathered forms an entirely new reference range which has the potential to revolutionize how diseases of the stress hormone system are diagnosed and treated."

Related Links:
University of Bristol


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.